Publications by authors named "Carlos Rodriguez Escalera"
Personalized cardiovascular risk assessment in Rheumatoid Arthritis patients using circulating molecular profiles and their modulation by TNFi, IL6Ri, and JAKinibs.
Biomed Pharmacother
April 2024
Article Synopsis
- The study investigated the inflammatory profiles of Rheumatoid Arthritis (RA) patients to identify those at higher risk for cardiovascular (CV) issues and evaluated the effects of specific medications.
- Researchers analyzed data from 387 RA patients, dividing them into groups based on prior CV events and treatment with disease-modifying drugs, while examining various inflammatory biomarkers.
- Findings revealed three distinct RA patient groups with varying inflammatory levels and CV risks, highlighting that certain treatments effectively lowered disease activity and improved inflammatory markers associated with CV risk, suggesting a pathway for personalized management in RA care.
Background: Belimumab was the first biological drug approved for Systemic Lupus Erythematosus (SLE). There is not a review focusing on all real-life experience with belimumab to date that could help to describe how this drug behaves in the Spanish clinical setting.
Objective: To describe the characteristics of SLE patients treated with belimumab added to standard of care in real-clinical setting in Spain.
Integrative Clinical, Molecular, and Computational Analysis Identify Novel Biomarkers and Differential Profiles of Anti-TNF Response in Rheumatoid Arthritis.
Front Immunol
September 2021
This prospective multicenter study developed an integrative clinical and molecular longitudinal study in Rheumatoid Arthritis (RA) patients to explore changes in serologic parameters following anti-TNF therapy (TNF inhibitors, TNFi) and built on machine-learning algorithms aimed at the prediction of TNFi response, based on clinical and molecular profiles of RA patients. A total of 104 RA patients from two independent cohorts undergoing TNFi and 29 healthy donors (HD) were enrolled for the discovery and validation of prediction biomarkers. Serum samples were obtained at baseline and 6 months after treatment, and therapeutic efficacy was evaluated.
View Article and Find Full Text PDFDisease-modifying antirheumatic drug prescription patterns in adult rheumatoid arthritis patients in routine clinical practice in Spain.
Eur J Rheumatol
September 2020
Objective: To describe disease-modifying antirheumatic drug (DMARD) patterns in routine clinical practice in adult rheumatoid arthritis (RA) patients and to ascertain the reasons for methotrexate (MTX) discontinuation.
Methods: A cross-sectional observational study was conducted from March to October 2014 at the Rheumatology Units of seven hospitals in Spain. In a single visit, the treating rheumatologist completed an online case report form.